## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 4.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($669.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Barclays Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $850**
- Source: 富途牛牛 | 20251209T150752 | Bullish | Relevance: 99%
-  Barclays analyst Balaji Prasad has maintained a Buy rating on IDEXX Laboratories Inc (IDXX.US) and significantly increased the target price from $520 to $850. This adjustment reflects a strong continued outlook for the company, according to the analyst's data provided by TipRanks.

**2. iSAM Funds UK Ltd Takes $1.85 Million Position in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251209T150814 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd has initiated a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX), acquiring 3,448 shares valued at approximately $1.85 million during the second quarter. This move contributes to the substantial institutional ownership of IDEXX, which now stands at about 87.84%. The company recently reported strong Q3 earnings, surpassing analyst estimates, and provided positive FY2025 guidance, with a consensus analyst price target of $763.50 indicating a "Moderate Buy" rating.

**3. IDEXX Laboratories, Inc. $IDXX Shares Purchased by California Public Employees Retirement System**
- Source: MarketBeat | 20251209T102318 | Somewhat-Bullish | Relevance: 99%
- The California Public Employees Retirement System increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% in the second quarter, bringing its total holdings to 148,408 shares valued at $79.6 million. Other institutional investors also adjusted their positions, while an IDEXX executive recently sold over 9,000 shares. The company reported strong Q3 earnings, exceeding analyst expectations, and has a consensus "Moderate Buy" rating from analysts.

**4. IDEXX Laboratories (IDXX) with Overweight Recommendation**
- Source: Nasdaq | 20251209T230849 | Bullish | Relevance: 97%
- Barclays has initiated coverage of IDEXX Laboratories (IDXX) with an Overweight recommendation, citing a projected 9.41% upside from its current price and an average one-year price target of $773.18/share. The report also highlights strong institutional interest, with 2,163 funds holding positions, and a bullish put/call ratio of 0.96. While annual revenue is projected to decrease slightly by 1.52%, non-GAAP EPS is expected to be 12.41.

**5. IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251209T070825 | Bullish | Relevance: 97%
- IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $763.50. The company recently exceeded quarterly earnings estimates, reporting $3.22 EPS against an expected $3.14, and generated $1.11 billion in revenue, beating forecasts of $1.07 billion. Insider selling by EVP Nimrata Hunt (9,425 shares at $703.34) reduced her stake by 30.8%, while institutional investors hold a significant 87.84% of the company's stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.22 signals overvaluation risk, limited margin of safety. Forward P/E 49.1x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.6B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.22 |
| Forward P/E | 49.1 |
| Current P/E | 54.8 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.7% to -2.0% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-5.99), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.98% (CS: 16) | Neutral |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | -5.99 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $707.50
- **Stop Loss:** $669.18 (5.4% risk)
- **Target:** $745.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $25,470.00
- **Portfolio %:** 25.47%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*